Dengue virus photo-inactivated in presence of 1,5-iodonaphthylazide (INA) or AMT, a psoralen compound (4′-aminomethyl-trioxsalen) is highly immunogenic in mice

References

• Halstead SB. Dengue. Lancet 2007; 370:1644 - 52; http://dx.doi.org/10.1016/S0140-6736(07)61687-0; PMID: 17993365
   PubMed Web of Science ®Google Scholar
• Simmons CP, Farrar JJ, Nguyen V, Wills B. Dengue. N Engl J Med 2012; 366:1423 - 32; http://dx.doi.org/10.1056/NEJMra1110265; PMID: 22494122
   PubMed Web of Science ®Google Scholar
• Kliks SC, Nimmanitya S, Nisalak A, Burke DS. Evidence that maternal dengue antibodies are important in the development of dengue hemorrhagic fever in infants. Am J Trop Med Hyg 1988; 38:411 - 9; PMID: 3354774
   PubMed Web of Science ®Google Scholar
• Kliks SC, Nisalak A, Brandt WE, Wahl L, Burke DS. Antibody-dependent enhancement of dengue virus growth in human monocytes as a risk factor for dengue hemorrhagic fever. Am J Trop Med Hyg 1989; 40:444 - 51; PMID: 2712199
   PubMed Web of Science ®Google Scholar
• Sun W, Cunningham D, Wasserman SS, Perry J, Putnak JR, Eckels KH, et al. Phase 2 clinical trial of three formulations of tetravalent live-attenuated dengue vaccine in flavivirus-naïve adults. Hum Vaccin 2009; 5:33 - 40; http://dx.doi.org/10.4161/hv.5.1.6348; PMID: 18670195
   PubMed Web of Science ®Google Scholar
• Edelman R, Wasserman SS, Bodison SA, Putnak RJ, Eckels KH, Tang D, et al. Phase I trial of 16 formulations of a tetravalent live-attenuated dengue vaccine. Am J Trop Med Hyg 2003; 69:Suppl 48 - 60; PMID: 14740955
   PubMed Web of Science ®Google Scholar
• Robert Putnak J, Coller BA, Voss G, Vaughn DW, Clements D, Peters I, et al. An evaluation of dengue type-2 inactivated, recombinant subunit, and live-attenuated vaccine candidates in the rhesus macaque model. Vaccine 2005; 23:4442 - 52; http://dx.doi.org/10.1016/j.vaccine.2005.03.042; PMID: 16005749
   PubMed Web of Science ®Google Scholar
• Coller BA, Clements DE, Bett AJ, Sagar SL, Ter Meulen JH. The development of recombinant subunit envelope-based vaccines to protect against dengue virus induced disease. Vaccine 2011; 29:7267 - 75; http://dx.doi.org/10.1016/j.vaccine.2011.07.021; PMID: 21777637
   PubMed Web of Science ®Google Scholar
• Durbin AP, Whitehead SS. Next-generation dengue vaccines: novel strategies currently under development. Viruses 2011; 3:1800 - 14; http://dx.doi.org/10.3390/v3101800; PMID: 22069516
   PubMed Web of Science ®Google Scholar
• Guy B, Barrere B, Malinowski C, Saville M, Teyssou R, Lang J. From research to phase III: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine. Vaccine 2011; 29:7229 - 41; http://dx.doi.org/10.1016/j.vaccine.2011.06.094; PMID: 21745521
   PubMed Web of Science ®Google Scholar
• Kliks S. Antibody-enhanced infection of monocytes as the pathogenetic mechanism for severe dengue illness. AIDS Res Hum Retroviruses 1990; 6:993 - 8; PMID: 2223245
   PubMed Web of Science ®Google Scholar
• Beckett CG, Tjaden J, Burgess T, Danko JR, Tamminga C, Simmons M, et al. Evaluation of a prototype dengue-1 DNA vaccine in a Phase 1 clinical trial. Vaccine 2011; 29:960 - 8; http://dx.doi.org/10.1016/j.vaccine.2010.11.050; PMID: 21111785
   PubMed Web of Science ®Google Scholar
• Raviprakash K, Apt D, Brinkman A, Skinner C, Yang S, Dawes G, et al. A chimeric tetravalent dengue DNA vaccine elicits neutralizing antibody to all four virus serotypes in rhesus macaques. Virology 2006; 353:166 - 73; http://dx.doi.org/10.1016/j.virol.2006.05.005; PMID: 16814355
   PubMed Web of Science ®Google Scholar
• Raviprakash K, Kochel TJ, Ewing D, Simmons M, Phillips I, Hayes CG, et al. Immunogenicity of dengue virus type 1 DNA vaccines expressing truncated and full length envelope protein. Vaccine 2000; 18:2426 - 34; http://dx.doi.org/10.1016/S0264-410X(99)00570-8; PMID: 10738100
   PubMed Web of Science ®Google Scholar
• Raviprakash K, Luke T, Doukas J, Danko J, Porter K, Burgess T, et al. A dengue DNA vaccine formulated with Vaxfectin (®) is well tolerated, and elicits strong neutralizing antibody responses to all four dengue serotypes in New Zealand white rabbits. Hum Vaccin Immunother 2012; 8:1764 - 8; http://dx.doi.org/10.4161/hv.21806; PMID: 23032166
   PubMed Web of Science ®Google Scholar
• Holman DH, Wang D, Raviprakash K, Raja NU, Luo M, Zhang J, et al. Two complex, adenovirus-based vaccines that together induce immune responses to all four dengue virus serotypes. Clin Vaccine Immunol 2007; 14:182 - 9; http://dx.doi.org/10.1128/CVI.00330-06; PMID: 17192403
   PubMed Web of Science ®Google Scholar
• Raviprakash K, Wang D, Ewing D, Holman DH, Block K, Woraratanadharm J, et al. A tetravalent dengue vaccine based on a complex adenovirus vector provides significant protection in rhesus monkeys against all four serotypes of dengue virus. J Virol 2008; 82:6927 - 34; http://dx.doi.org/10.1128/JVI.02724-07; PMID: 18480438
   PubMed Web of Science ®Google Scholar
• Putnak R, Barvir DA, Burrous JM, Dubois DR, D’Andrea VM, Hoke CH, et al. Development of a purified, inactivated, dengue-2 virus vaccine prototype in Vero cells: immunogenicity and protection in mice and rhesus monkeys. J Infect Dis 1996; 174:1176 - 84; http://dx.doi.org/10.1093/infdis/174.6.1176; PMID: 8940206
   PubMed Web of Science ®Google Scholar
• Fraenkel-Conrat H, Mecham DK. The reaction of formaldehyde with proteins; demonstration of intermolecular cross-linking by means of osmotic pressure measurements. J Biol Chem 1949; 177:477 - 86; PMID: 18107450
   PubMed Web of Science ®Google Scholar
• Mason JT, O’Leary TJ. Effects of formaldehyde fixation on protein secondary structure: a calorimetric and infrared spectroscopic investigation. J Histochem Cytochem 1991; 39:225 - 9; http://dx.doi.org/10.1177/39.2.1987266; PMID: 1987266
   PubMed Web of Science ®Google Scholar
• Nowace, JM. Fixation and Tissue Processing. 2010;141-152
   Google Scholar
• Raviv Y, Viard M, Bess JW Jr., Chertova E, Blumenthal R. Inactivation of retroviruses with preservation of structural integrity by targeting the hydrophobic domain of the viral envelope. J Virol 2005; 79:12394 - 400; http://dx.doi.org/10.1128/JVI.79.19.12394-12400.2005; PMID: 16160166
   PubMed Web of Science ®Google Scholar
• Hanson CV, Riggs JL, Lennette EH. Photochemical inactivation of DNA and RNA viruses by psoralen derivatives. J Gen Virol 1978; 40:345 - 58; http://dx.doi.org/10.1099/0022-1317-40-2-345; PMID: 211184
   PubMed Web of Science ®Google Scholar
• Sabchareon A, Wallace D, Sirivichayakul C, Limkittikul K, Chanthavanich P, Suvannadabba S, et al. Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial. Lancet 2012; 380:1559 - 67; http://dx.doi.org/10.1016/S0140-6736(12)61428-7; PMID: 22975340
   PubMed Web of Science ®Google Scholar
• Hilleman MR. Hepatitis and hepatitis A vaccine: a glimpse of history. J Hepatol 1993; 18:Suppl 2 S5 - 10; http://dx.doi.org/10.1016/S0168-8278(05)80370-8; PMID: 8182274
   PubMedGoogle Scholar
• Barrett PN, Dorner F, Plotkin SA. Tick-Borne Encephalitis Vaccine. Vaccines, 3rd Ed. Editors Plotkin SA and Orenstein WA, 767-780 (1999).
   Google Scholar
• Tsai TF. C. G. a. Y. Y. Japanese encephalitis vaccines. Vaccines, 3rd Ed. Editors Plotkin SA and Orenstein WA, 672-710 (1999).
   Google Scholar
• Murdin AD, Inactivated Virus Vaccines RBSS. New Vaccine Technologies, Ed: Ellis RW., 133-150 (2001).
   Google Scholar
• Putnak R, Cassidy K, Conforti N, Lee R, Sollazzo D, Truong T, et al. Immunogenic and protective response in mice immunized with a purified, inactivated, Dengue-2 virus vaccine prototype made in fetal rhesus lung cells. Am J Trop Med Hyg 1996; 55:504 - 10; PMID: 8940981
   PubMed Web of Science ®Google Scholar
• Brown F. Review of accidents caused by incomplete inactivation of viruses. Dev Biol Stand 1993; 81:103 - 7; PMID: 8174792
   PubMedGoogle Scholar
• Kim HW, Canchola JG, Brandt CD, Pyles G, Chanock RM, Jensen K, et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol 1969; 89:422 - 34; PMID: 4305198
   PubMed Web of Science ®Google Scholar
• Gaspar LP, Mendes YS, Yamamura AM, Almeida LF, Caride E, Gonçalves RB, et al. Pressure-inactivated yellow fever 17DD virus: implications for vaccine development. J Virol Methods 2008; 150:57 - 62; http://dx.doi.org/10.1016/j.jviromet.2008.03.002; PMID: 18420285
   PubMed Web of Science ®Google Scholar
• Maves RC, Castillo Oré RM, Porter KR, Kochel TJ. Immunogenicity of a psoralen-inactivated dengue virus type 1 vaccine candidate in mice. Clin Vaccine Immunol 2010; 17:304 - 6; http://dx.doi.org/10.1128/CVI.00353-09; PMID: 20007362
   PubMed Web of Science ®Google Scholar
• Maves RC, Oré RM, Porter KR, Kochel TJ. Immunogenicity and protective efficacy of a psoralen-inactivated dengue-1 virus vaccine candidate in Aotus nancymaae monkeys. Vaccine 2011; 29:2691 - 6; http://dx.doi.org/10.1016/j.vaccine.2011.01.077; PMID: 21303709
   PubMed Web of Science ®Google Scholar
• Raviv Y, Blumenthal R, Tompkins SM, Humberd J, Hogan RJ, Viard M. Hydrophobic inactivation of influenza viruses confers preservation of viral structure with enhanced immunogenicity. J Virol 2008; 82:4612 - 9; http://dx.doi.org/10.1128/JVI.02233-07; PMID: 18305038
   PubMed Web of Science ®Google Scholar
• Sharma A, Gupta P, Glass PJ, Parker MD, Maheshwari RK. Safety and protective efficacy of INA-inactivated Venezuelan equine encephalitis virus: implication in vaccine development. Vaccine 2011; 29:953 - 9; http://dx.doi.org/10.1016/j.vaccine.2010.11.033; PMID: 21115048
   PubMed Web of Science ®Google Scholar
• Sagripanti JL, Marschall HJ, Voss L, Hülseweh B. Photochemical inactivation of alpha- and poxviruses. Photochem Photobiol 2011; 87:1369 - 78; http://dx.doi.org/10.1111/j.1751-1097.2011.00998.x; PMID: 21895667
   PubMed Web of Science ®Google Scholar
• Raviprakash K, Porter KR, Kochel TJ, Ewing D, Simmons M, Phillips I, et al. Dengue virus type 1 DNA vaccine induces protective immune responses in rhesus macaques. J Gen Virol 2000; 81:1659 - 67; PMID: 10859370
   PubMed Web of Science ®Google Scholar
• Chen L, Ewing D, Subramanian H, Block K, Rayner J, Alterson KD, et al. A heterologous DNA prime-Venezuelan equine encephalitis virus replicon particle boost dengue vaccine regimen affords complete protection from virus challenge in cynomolgus macaques. J Virol 2007; 81:11634 - 9; http://dx.doi.org/10.1128/JVI.00996-07; PMID: 17715224
   PubMed Web of Science ®Google Scholar